Legend Biotech (LEGN) moved back into focus after releasing five-year follow-up data from its CARTITUDE-2 Cohort A study of CARVYKTI in relapsed or refractory multiple myeloma patients.
Despite the encouraging CARTITUDE-2 update, Legend Biotech’s recent trading tells a more cautious story. The share price is down about 3.9% over the past day and roughly 13.7% over 30 days, contributing to a 1-year total shareholder return decline of 42.1% and a 5-year total shareholder return decline of 65.3%. This signals fading momentum as investors reassess both opportunity and risk around CARVYKTI’s long-term profile.
Scan beyond Legend Biotech and line up other potential rebound stories in high-risk, high-reward territory with the hand-picked 8 elite penny stocks with strong financials.
Legend Biotech appears to have a compelling therapy story, yet the share price has slipped significantly over the past year. Is this a strong business being mispriced, or is the recent drop a fair reset of expectations?
Most Popular Narrative: 60% Undervalued
Legend Biotech last closed at $18.57, while the most followed narrative assigns a fair value of about $46.81. As a result, the gap between price and expectations is wide and puts the focus squarely on the long-term CAR-T story.
Robust innovation pipeline, including next-generation CAR-Ts and in vivo/off-the-shelf cell therapy technologies (e.g., TaVec platform), positions Legend to capitalize on rising demand for advanced, personalized therapies amid secular increases in cancer incidence and sustained healthcare investment, supporting future revenue streams and risk diversification.
See why 26 investors see Legend Biotech as 60% undervalued.
That framework uses a 7.62% discount rate and ties the $46.81 fair value to analyst expectations for revenue growth, profitability and margins over the coming years, rather than to last quarter’s headlines. The result is a narrative that views recent share price weakness alongside forecasts that Legend Biotech could move from a loss of $91.5 million today to meaningful earnings if those assumptions play out.
Result: Fair Value of $46.81 (UNDERVALUED)
Still, the bullish Legend Biotech narrative could unravel quickly if CARVYKTI loses share to rival therapies or if heavy R&D spend delays any path to profitability.
Find out about the key risks to this Legend Biotech narrative.
Next Steps
Mixed messages on Legend Biotech so far, right? If the story feels incomplete, move quickly, review the data yourself, then weigh the 4 key rewards
Leave a comment